Frailty and Effects of Semaglutide in Obesity-Related HFpEF
JACC: Heart Failure · 2025-10 · 13 (10) · 102610
DOI: 10.1016/j.jchf.2025.102610 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JACC: Heart Failure, 2025-10. Verfasst von Ambarish Pandey und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Division of Geriatrics,…. Hauptthemen laut MEDLINE: Frailty, Heart Failure, Obesity, Stroke Volume. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
BACKGROUND: Frailty is common in heart failure with preserved ejection fraction (HFpEF). In the STEP-HFpEF (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity) program, semaglutide improved heart failure (HF) symptoms and physical limitations and reduced body weight (BW) in participants with obesity-related HFpEF. Whether the efficacy and safety of semaglutide vary by frailty and the effects of semaglutide on frailty are unknown. OBJECTIVES: This study sought to evaluate the efficacy of semaglutide in participants with obesity-related HFpEF according to frailty status at baseline. METHODS: The authors performed a prespecified, pooled, participant-level analysis of the STEP-HFpEF program that included participants with obesity-related HFpEF. Participants were randomized to once-weekly semaglutide, 2.4 mg, or placebo for 52 weeks. Dual primary endpoints were changes in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) and BW. Frailty was estimated using a cumulative deficit-derived frailty index comprising 34 variables across multiple domains at baseline and follow-up. Efficacy and safety of semaglutide were evaluated in participants across 3 baseline frailty strata. Effects of semaglutide on frailty burden were also assessed. RESULTS: Of the 1,145 participants, 110 (9.6%) were nonfrail, 343 (30.0%) were more frail, and 692 (60.4%) were most frail. Semaglutide-mediated weight loss was similar across frailty strata (Pinteraction = 0.38). However, the effects of semaglutide on KCCQ-CSS varied by frailty status; participants who were most frail had the greatest improvement at 52 weeks (nonfrail mean difference: -1.5 [95% CI: -8.4 to 5.4]; more frail mean difference: 3.7 [95% CI: -0.2 to 7.6]; most frail mean difference: 11.0 [95% CI: 8.1-13.8]; Pinteraction < 0.001). Semaglutide reduced the burden of frailty during follow-up (OR for being nonfrail at 52 weeks: 3.16 [95% CI: 2.44-4.09]; P < 0.0001). CONCLUSIONS: Semaglutide resulted in a similar reduction in BW across frailty subgroups but greater improvements in HF-related symptoms. Moreover, semaglutide reduced frailty burden after 52 weeks of treatment. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF]; NCT04788511) (Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes [STEP-HFpEF DM]; NCT04916470).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Division of Geriatrics, Department of Internal Medicine, University of Texas Southwestern Med…
- Section on Cardiovascular Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA; Section on Geriatrics/Gerontology, Department of Internal Medicine, Wak…
- Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Baylor Scott and White Research Institute, Dallas, Texas, USA.
- Diabetes Research Centre, University of Leicester, Leicester, United Kingdom; NIHR (National Institute for Health and Care Research) Leicester Biomedical Research Centre, Leicester, United Kingdom.
Förderung
- Novo Nordisk
Zitieren
APA
Pandey, A., Kitzman, D. W., Chinnakondepalli, K. M., Patel, S., Borlaug, B. A., Butler, J., Davies, M. J., Shah, S. J., Verma, S., Rönnbäck, C., Domdey, A., Liisberg, K., Schou, M., Perna, E., Ahmed, F. Z., Fu, M., Petrie, M. C., & Kosiborod, M. N. (2025). Frailty and Effects of Semaglutide in Obesity-Related HFpEF. JACC: Heart Failure, 13(10), 102610. https://doi.org/10.1016/j.jchf.2025.102610
Vancouver
Pandey A, Kitzman DW, Chinnakondepalli KM, Patel S, Borlaug BA, Butler J, et al. Frailty and Effects of Semaglutide in Obesity-Related HFpEF. JACC: Heart Failure. 2025;13(10):102610. doi:10.1016/j.jchf.2025.102610
BibTeX
@article{Pandey2025,
author = {Pandey, Ambarish and Kitzman, Dalane W and Chinnakondepalli, Khaja M and Patel, Shachi and Borlaug, Barry A and Butler, Javed and Davies, Melanie J and Shah, Sanjiv J and Verma, Subodh and Rönnbäck, Cecilia and Domdey, Anne and Liisberg, Karoline and Schou, Morten and Perna, Eduardo and Ahmed, Fozia Z and Fu, Michael and Petrie, Mark C and Kosiborod, Mikhail N},
title = {Frailty and Effects of Semaglutide in Obesity-Related HFpEF},
journal = {JACC: Heart Failure},
year = {2025},
volume = {13},
number = {10},
pages = {102610},
doi = {10.1016/j.jchf.2025.102610}
}
EUVIMED